Arabic Arabic English English French French German German
dark

Lexicon’s Sotagliflozin Demonstrates Additional Compelling Benefits in Reducing Cardiovascular Endpoints: Results from Soloist and Scored Trials

Lexicon Pharmaceuticals, Inc., presented additional analyses of sotagliflozin data from the SOLOIST and SCORED Phase 3 clinical trials at ESC Congress 2021 – The Digital Experience. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

How Patient Interactive Systems Minimizes Nurse Burnout & Facilitates Patient Education

Next Post

Kelyniam Global Releases 2nd Quarter 2021 Financials Maintains Profitability – Covid Challenges Continue

Related Posts
Total
0
Share